HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Adamson, J. W. Search for Related Content PubMed PubMed Citation Articles by Adamson, J. W. Social Bookmarking                   What's this?

The Anemia of Inflammation/Malignancy: Mechanisms and Management

Correspondence: John W. Adamson, MD, VA Medical Center MC 111E, 3350 La Jolla Village Dr, San Diego, CA 92161; Phone: 858-552-8585; ext 3348; Fax: 858-552-7485; e-mail: john.adamson2{at}va.gov; jadamson{at}ucsd.edu

Abstract

Anemia is a common complication in patients with inflammatory diseases of many kinds, including cancer. The mechanisms that have captured the most attention include cytokine-mediated changes in both the production of and the response to erythropoietin (Epo), as well as important alterations in iron metabolism. The last is brought about by the relatively recently recognized peptide hormone, hepcidin. The availability of recombinant human Epo and its derivatives (known by class as Erythropoietic Stimulating Agents, ESAs) has dramatically changed anemia management in patients with cancer but, in the process, has raised as many issues as have been answered. This chapter reviews the mechanisms resulting in anemia in inflammation, including cancer, and focuses on the controversies around management with the ESAs and the adjuvant use of iron in anemia management.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?